---
mi_id: MIPR-node_b6d53f0
type: press_release
canonical_url: "https://www.pheonixresearch.com/healthcare/diagnostics/press-release/twenty-eight-per-cent-of-diagnostics-no-vendor-above-twelve-code-families-cut/"
md_url: "https://www.pheonixresearch.com/healthcare/diagnostics/press-release/twenty-eight-per-cent-of-diagnostics-no-vendor-above-twelve-code-families-cut.md"

schema:
  "@type": NewsArticle
  "@id": MIPR-node_b6d53f0
  url: "https://www.pheonixresearch.com/healthcare/diagnostics/press-release/twenty-eight-per-cent-of-diagnostics-no-vendor-above-twelve-code-families-cut/"
  title: Twenty-Eight Per Cent of Diagnostics and No Vendor Above Twelve — and the Two Code Families That Pay for It Were Cut 22 and 19.3 Per Cent
  description: "USD 30,150m in 2025 to USD 44,040m in 2033 at 4.85%. The largest field in IVD at 28.74% with no vendor above 11.86%, and two code families cut 22% and 19.3%."
  datePublished: "2026-11-15T12:22:38+00:00"
  dateModified: "2026-11-15T12:22:38+00:00"
  keywords:
    - infectious disease diagnostics market
    - infectious disease diagnostics market size
    - infectious disease diagnostics forecast 2033
    - syndromic panels market
    - blood culture market
    - molecular pathology fee schedule
    - microbiology reimbursement
    - IVD market share
  isPartOf:
    - id: MISG-node_7e576db
      type: CollectionPage
      url: "https://www.pheonixresearch.com/healthcare/diagnostics/"
      name: Diagnostics
    - id: MIIN-node_50b4dbf
      type: CollectionPage
      url: "https://www.pheonixresearch.com/healthcare/"
      name: Healthcare
    - id: MIWS-root
      type: WebSite
      url: "https://www.pheonixresearch.com/"
      name: Pheonix Research

acf:
  phoenix_meta_title: "Infectious Disease Diagnostics Market 2026-2033: USD 30,150m to USD 44,040m"
  phoenix_meta_description: "USD 30,150m in 2025 to USD 44,040m in 2033 at 4.85%. The largest field in IVD at 28.74% with no vendor above 11.86%, and two code families cut 22% and 19.3%."

global_schema:
  organization:
    "@id": MIWS-root#organization
    "@type": Organization
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  website:
    "@id": MIWS-root
    "@type": WebSite
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  api:
    "@id": MIWS-root#api
    "@type": WebAPI
    url: "https://www.pheonixresearch.com/"

graph:
  node_id: MIPR-node_b6d53f0
  graph_node_endpoint: "https://graph.pheonixresearch.com/api/v1/query/live/node/MIPR-node_b6d53f0"
  graph_snapshot: "https://graph.pheonixresearch.com/api/v1/read/live/graph"
  graph_exclusions: "https://graph.pheonixresearch.com/api/v1/read/live/exclusions"
  graph_meta: "https://graph.pheonixresearch.com/api/v1/read/live/meta"
  graph_bundle: "https://graph.pheonixresearch.com/api/v1/read/live/bundle"

discovery:
  discovery_json: "https://www.pheonixresearch.com/.well-known/pheonix-discovery.json"
  llms_txt: "https://www.pheonixresearch.com/llms.txt"
  sitemap: "https://www.pheonixresearch.com/sitemap.xml"
---
# Twenty-Eight Per Cent of Diagnostics and No Vendor Above Twelve — and the Two Code Families That Pay for It Were Cut 22 and 19.3 Per Cent

Pheonix Research has published *Global Infectious Disease Diagnostics Market Report, Size, Share and Forecast 2026-2033: Twenty-Eight Per Cent of Diagnostics and No Vendor Above Twelve*, which sizes the field at **USD 30,150 million in 2025**, reaching **USD 44,040 million by 2033** at a compound annual rate of **4.85 per cent** — an increment of **USD 13,890 million**, or **1.46 times** the base year. The full report is available at [pheonixresearch.com](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-infectious-disease-diagnostics-market/).

The finding is a concentration anomaly with a pricing mechanism attached. Infectious disease diagnostics is the largest application area in in vitro diagnostics — **28.74 per cent of the USD 104.9 billion base**, ahead of immunoassay at 25.2 per cent, clinical chemistry at 16.0 per cent, microbiology at 8.4 per cent and haematology at 7.3 per cent — and it is the only one of those fields that no vendor owns. The largest pool in the market is Abbott at **USD 3,577 million, or 11.86 per cent**, against Sysmex at 18.3 per cent of haematology and bioMérieux at 17.1 per cent of microbiology. And the price of this field is not set by any of those vendors. It is set by Medicare's clinical laboratory fee schedule and by donor procurement — and both were cut.

## The largest field in diagnostics is the only one nobody owns

Attribution in this report is built bottom-up from company disclosure to thirteen named pools totalling **USD 17,984 million, 59.65 per cent** of the field, against a stated residual of **USD 12,166 million, 40.35 per cent** held by manufacturers that cannot be individually named. The top five pools hold **42.27 per cent**. Hard disclosure — a company publishing a line we can use rather than an allocation we made — covers three companies and **USD 6,759 million, or 22.42 per cent**: Abbott's three reported diagnostic lines, bioMérieux's two application lines, and Qiagen's diagnostic solutions.

That is the largest residual in this cluster, and it is structural rather than an accident of disclosure. The perimeter of this field is a clinical question — is there a pathogen, and which one — not a technology or a platform. A vendor can own a discipline, because a discipline is a technique; no vendor owns a question that every technique answers. The same specimen can be worked up as a culture, a panel, an antigen test or a sequencing run, and each of those sits inside a different platform franchise's balance sheet. The report's competitive landscape section shows the consequence inside one company: Abbott's infectious-disease position is a rapid-diagnostics franchise at **USD 2,454 million** and a laboratory molecular business at **USD 517 million**. Abbott leads this field not by winning the laboratory but by owning the channel closest to the patient.

## Volume compounds at 5.49 per cent and revenue at 4.85 — and the gap is the product

Test volume goes from **6,000 million tests to 9,200 million**, up 53.3 per cent, compounding at **5.49 per cent** against revenue growth of 4.85 per cent. Realised revenue per test therefore falls from **USD 5.025 to USD 4.787** — down 4.7 per cent across the window and **0.61 per cent a year**.

Decomposed, that 64 basis point gap is two things moving in opposite directions.

 | Component |  | Annual effect |  | Mechanism |

 | Volume |  | +5.49% |  | Ageing, antimicrobial resistance burden, low- and middle-income access, panel ordering per admission |

 | Constant-menu price |  | −2.10% |  | Volume-based procurement, fee-schedule reduction, competitive tendering, donor price ceilings |

 | Mix |  | +1.49 pts |  | Syndromic panels and metagenomics taking share of the base |

 | Net revenue per test |  | −0.61% |  |  |

The mix contribution is the whole of this field's pricing power, and it is finite by construction. A panel raises the average only while it is displacing single-target tests. Once a hospital has converted its respiratory and gastrointestinal ordering to panels, the mix effect stops adding and the constant-menu decline is what remains. On the report's own arithmetic, once syndromic and metagenomic share plateaus at roughly 26 to 27 per cent of the base, revenue growth converges on volume growth minus the price cut — in the region of **3.2 to 3.5 per cent**.

## The growth that is real is menu, not price

The seven segments sum to the total in both years, and they are defined by the question the test answers rather than the instrument it runs on — which is why one vendor appears in five of them.

 | Segment |  | 2025 (USD m) |  | 2033 (USD m) |  | CAGR |  | Share of base |  | Share of increment |

 | Laboratory microbiology — culture, identification, susceptibility |  | 8,830 |  | 13,190 |  | 5.14% |  | 29.29% |  | 31.39% |

 | Molecular syndromic and multiplex panels |  | 6,300 |  | 10,400 |  | 6.46% |  | 20.90% |  | 29.52% |

 | Serology and immunoassay pathogen detection |  | 5,900 |  | 7,600 |  | 3.21% |  | 19.57% |  | 12.24% |

 | Rapid antigen and point-of-care testing |  | 4,300 |  | 5,500 |  | 3.12% |  | 14.26% |  | 8.64% |

 | Viral load and treatment monitoring |  | 2,900 |  | 4,000 |  | 4.10% |  | 9.62% |  | 7.92% |

 | Blood donor and transplant infectious screening |  | 1,500 |  | 2,150 |  | 4.61% |  | 4.98% |  | 4.68% |

 | Metagenomic and sequencing-based identification |  | 420 |  | 1,200 |  | 14.02% |  | 1.39% |  | 5.62% |

 | Total |  | 30,150 |  | 44,040 |  | 4.85% |  | 100.0% |  | 100.0% |

The two slowest segments — serology at 3.21 per cent and rapid antigen and point-of-care at 3.12 per cent — are **33.83 per cent of the base and 20.88 per cent of the increment**. The two fastest, syndromic panels and metagenomics, are **22.29 per cent of the base and 35.13 per cent of the increment**. The volume is where the money isn't: a malaria rapid test is sold for cents and a fifteen-target respiratory panel for tens of dollars, and the first is growing in units faster than the second grows in dollars.

Laboratory microbiology is the exception and it is the only segment in this field with a rising revenue per test — which is why it is sized separately in Pheonix Research's microbiology report and is not counted twice here.

## The two code families that pay for this field were both cut

Medicare laboratory rates are set under PAMA from the weighted median of private payor rates reported by applicable laboratories. The 2026 reporting cycle covered January to June 2025 and was reported between May and July 2026: **6,411 laboratories submitted, 6,304 survived exclusions, and 1,528 of 1,947 codes produced a weighted median**. Hospital laboratories rose from about **1.1 per cent of reporting entities in 2017 to roughly 13.6 per cent now** — and that is the mechanism worth holding, because as hospital laboratories come to dominate the reporting base, the private rates that determine Medicare's rates are increasingly other hospitals' negotiated rates.

The preliminary calendar 2027 clinical laboratory fee schedule is what that mechanism produces: **molecular pathology down 22 per cent, microbiology down 19.3 per cent and chemistry down 16 per cent**, with reductions capped at **15 per cent a year from 2027 to 2029**. The cap does not forgive the difference. It defers it, and it defers it into exactly the years this forecast treats as its growth period.

There is no code family in which this field is sheltered. A syndromic respiratory panel is billed in molecular pathology and a culture and susceptibility in microbiology, so the field's two payment routes were cut in the same schedule.

## The volume is in the places that pay least

 | Region |  | 2025 (USD m) |  | Share |  | Character of demand |

 | North America |  | 11,150 |  | 37.0% |  | Highest revenue per test; payer-managed panel coverage; administered fee schedule |

 | Europe |  | 7,240 |  | 24.0% |  | Public procurement; IVDR conformity cost; strong microbiology and serology base |

 | China |  | 3,920 |  | 13.0% |  | Provincial volume-based procurement; domestic substitution; the price floor of the field |

 | Japan |  | 1,810 |  | 6.0% |  | National fee schedule; mature, demographically contracting |

 | Rest of world |  | 6,030 |  | 20.0% |  | Donor-funded procurement; 60 per cent of volume on roughly 20 per cent of revenue |

 | Total |  | 30,150 |  | 100.0% |  |  |

North America is 37.0 per cent of revenue and a far smaller share of tests; the rest of the world is 20.0 per cent of revenue and the majority of the volume. Any forecast of this field that does not separate count from price overstates it in exactly the geographies where the count is growing. The product split says the same thing from another direction: **reagents, cartridges and consumables are 60.0 per cent** of the field at USD 18,090 million, instruments 20.0 per cent, services 13.0 per cent and software 7.0 per cent — the highest consumable share of any discipline in the cluster. Qiagen reports the shape explicitly, with consumables and related revenue at **USD 1,876.4 million, 90 per cent of net sales, growing 7 per cent**, against instrumentation at **USD 213.6 million, 10 per cent of sales, declining 2 per cent**. The instrument is a placement decision. The cartridge is the business.

## The risk register is a budget line, not a competitor

Viral load and treatment monitoring at USD 2,900 million, and the tuberculosis molecular testing inside the diagnostics the WHO tracks, are procured by donors and national programmes rather than by payers. Those segments are **9.62 per cent of the base and 7.92 per cent of the increment**, and the increment is what a forecast is. A quarter reduction in donor-funded volume from 2026 removes roughly **USD 900 million from the 2033 endpoint and takes the compound rate from 4.85 per cent to 3.47 per cent**. No clinical development, no product launch and no reimbursement decision offsets that, because none of them acts on the same buyer.

 | Scenario |  | 2033 (USD m) |  | CAGR |  | Condition |

 | Rapid substitution |  | 47,200 |  | 5.77% |  | Panels displace culture faster; metagenomics clears coverage; waived molecular takes the physician office |

 | Base |  | 44,040 |  | 4.85% |  |  |

 | Fee schedule lands in full |  | 41,300 |  | 4.02% |  | The CY2027 reductions are absorbed rather than deferred into 2030–2032 |

 | Funding withdrawal |  | 39,600 |  | 3.47% |  | Donor-funded viral load and tuberculosis testing contracts by a quarter from 2026 |

A 230 basis point band, and two of the four scenarios are government decisions rather than clinical or technological ones. That is the honest description of this field's uncertainty: it is not a question of whether the tests will be used. Bacterial antimicrobial resistance was associated with 4.71 million deaths in 2021 and 1.14 million were attributable to it, with projections of 8.22 million and 1.91 million by 2050; sepsis accounted for 48.9 million cases and 11.0 million deaths; tuberculosis produced 10.7 million cases and more than 1.2 million deaths in 2024, with rapid molecular testing reaching only 54 per cent of those diagnosed. Demand is not the constraint. The constraint is the price at which that need is met, and who pays.

The base year is also not clean. Abbott's COVID-19 testing-related sales fell from **USD 747 million in 2024 to USD 297 million in 2025**, and its Rapid Diagnostics line still declined **18.1 per cent** on the year, **20.8 per cent** in the United States, with that reduction already inside the comparison. A USD 450 million annual decline in one product family, two years after the emergency ended, is a base effect the whole field is still absorbing — and the direction of the residual correction is downward.

## What the companies disclose, and where the money actually is

**bioMérieux** is the only company here that publishes its syndromic lines separately, and the three lines describe the whole substitution inside one P&L: microbiology at **EUR 1,339 million, up 4 per cent** (up 6.3 per cent excluding China), the non-respiratory BIOFIRE panel at **EUR 598 million, up 10 per cent**, and SPOTFIRE at **EUR 168 million, up 84 per cent** with 6,400 instruments in the field, up 110 per cent. Group sales were EUR 4,070 million, up 6.2 per cent, with contributive EBIT of EUR 728 million at 17.9 per cent of sales growing 16 per cent organically. That ladder has to be read with the base in mind, because 84 per cent of 168 is a smaller number than 4 per cent of 1,339.

**Qiagen** diagnostic solutions grew **7 per cent to USD 803.1 million**, the fastest-growing disclosed infectious-disease line in the field, on QuantiFERON and more than **5,200 cumulative QIAstat-Dx placements**. **Roche**'s Diagnostics division grew 2 per cent at constant rates to CHF 13,847 million and introduced **53 new tests**, two instrument platforms and six digital solutions — among them a *cobas* liat Bordetella PCR test cleared with CLIA waiver and delivering a result in about fifteen minutes, which is a regulatory event that is really a channel decision. **Danaher**'s Diagnostics segment grew 1.5 per cent core inside a company that grew 2.0 per cent, with Cepheid respiratory revenue of roughly **USD 500 million in a single fourth quarter** — the cleanest annuity in the field and the most weather-dependent.

The capital movement is a reclassification rather than a bet. **Becton Dickinson** is combining its Biosciences and Diagnostic Solutions businesses with Waters Corporation, expected to complete around the end of the first quarter of calendar 2026 — which places the world's leading blood-culture franchise inside an analytical-instruments company, a statement about which multiple its growth rate supports.

## What this report is not

Infectious disease diagnostics is an application layer, not a discipline, and it should not be added to the discipline totals. Its perimeter is the clinical question rather than the technology or platform, so it intersects every discipline report in this cluster. Laboratory microbiology at USD 8,830 million is one of its seven segments and is sized separately in Pheonix Research's microbiology report; serology largely overlaps the immunoassay report. What this report answers is a different question: how much of the world's diagnostic spend is decided by an infectious-disease result, and who decides the price of that result.

## Scope and method

This report is built on a 70 per cent secondary and 30 per cent primary basis. The secondary construction is a bottom-up attribution from company disclosures, segment by segment, reconciled to a total and with the unattributed remainder stated rather than distributed. The primary programme comprised **38 depth interviews across 11 markets**, 24 open-ended interviews conducted through tender and procurement cycles, a **171-respondent laboratory and clinical survey**, and four conferences. Primary work is used to establish mechanism — how a panel is ordered, how a laboratory converts an instrument, how a procurement award becomes a price — and never to carry a figure. Every number traces to a disclosed source or to arithmetic on disclosed sources, and every allocation is labelled. Foreign-exchange basis is EUR 1.13 and CHF 1.15 per USD with JPY at 148, the same basis carried by the in vitro diagnostics hub and the rest of this cluster. The report contains no third-party market-research citations.

## Companion analysis

- The Largest Application Area in Diagnostics Has No Leader — no vendor above 11.86 per cent, a 40.35 per cent residual, and why the perimeter rather than the technology explains the fragmentation.

- The Pandemic Built the Point-of-Care Channel and the Channel Is Now Repricing — Abbott's COVID-19 testing sales fall 60.2 per cent, point-of-care becomes the slowest segment at 3.12 per cent, and Roche walks into the channel with a waived molecular test.

- The Two Families Infectious Disease Tests Are Paid In Were Both Cut — molecular pathology at minus 22 per cent and microbiology at minus 19.3 per cent, and why the mix that drove the growth is what moved the revenue into the path of the cut.

- The Largest Risk to Infectious Disease Diagnostics Is a Budget Line, Not a Competitor — donor-funded viral load and tuberculosis testing, and the arithmetic of a quarter reduction.

## About this report

The full report — with market definition and scope, executive summary, market size and forecast, the price inversion, competitive landscape, value chain and revenue model, technology and innovation, investment activity, market risk, regulatory landscape, regional analysis, end-market analysis, and research methodology and sources — is available at [https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-infectious-disease-diagnostics-market/](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-infectious-disease-diagnostics-market/).

## About Pheonix Research

Pheonix Research is a market intelligence platform that queries a live graph of more than 500 nodes across 25 industrial sectors to surface leading signals and translate them into role-specific decisions. Its premise is that companies operate in value chains rather than industries, and that a signal is only useful when it arrives with the context and the window to act on it.
